Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Next Previous
Search
Trial Profile

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abrocitinib (Primary) ; Dupilumab
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms JADE Compare
  • Sponsors Pfizer

Most Recent Events

  • 01 Oct 2023 Results of pooled analysis from JADE MONO-1 (NCT03349060), JADE MONO-2 (NCT03575871) and JADE COMPARE (NCT03720470) and JADE EXTEND assessing patient-reported outcomes with long-term abrocitinib treatment in patients with moderate-to-severe AD published in the Journal of the European Academy of Dermatology and Venereology
  • 01 Oct 2023 Results from three phase 3 studies( JADE MONO1 (NCT03349060), JADE MONO2 (NCT03575871) and JADE COMPARE (NCT03720470)), including the long term extension JADE EXTEND study(Data cut-off: April 22, 2020) evaluating efficacy of abrocitinib and long term safety in patients with moderate to severe AD, published in the Journal of the European Academy of Dermatology and Venereology.
  • 22 May 2023 Results of a post hoc analysis assessing the efficacy and safety of abrocitinib and dupilumab in a subset of patients with severe and/or difficult-to-treat atopic dermatitis, published in the American Journal of Clinical Dermatology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top